{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-224053","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.751231+00:00","generated_at":"2026-05-17T05:19:06.213472+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"enGene appoints Dr. Hussein Sweiti as CMO; former J&J bladder cancer lead","bullets":["Dr. Sweiti appointed Chief Medical Officer effective September 29, 2025.","Previously Global Medical Head, Oncology at J&J; led bladder cancer portfolio and recent FDA NMIBC approval.","Will oversee global clinical development for detalimogene; BLA submission planned for 2H 2026.","Brings 15+ years experience in surgical oncology, drug development, and regulatory submissions.","Appointed after target enrollment reached in pivotal detalimogene NMIBC trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-224053","json":"https://secwatch.observer/filing/0001193125-25-224053.json","markdown":"https://secwatch.observer/filing/0001193125-25-224053.md","text":"https://secwatch.observer/filing/0001193125-25-224053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312525224053/0001193125-25-224053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312525224053/engn-20250930.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:19:06.213472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}